Rainer F. Storb - Cancer Science

Author Information

Rainer F. Storb is affiliated with the Clinical Research Division at the Fred Hutchinson Cancer Research Center in Seattle, Washington, and also with the Department of Medicine at the University of Washington in Seattle, Washington. He is a prominent researcher known for his significant contributions to the field of hematopoietic cell transplantation and hematological malignancies.

Research Contributions

Rainer F. Storb has made substantial contributions to the field of cancer research, particularly in hematopoietic cell transplantation and hematologic malignancies. His work spans various innovative approaches, including non-myeloablative conditioning regimens, gene delivery techniques, and the use of radioimmunotherapy to overcome graft rejection. His research aims to improve the outcomes and reduce the complications associated with bone marrow and hematopoietic cell transplantation. Notable recent studies include the use of ultrasound-mediated gene delivery to achieve therapeutic levels of FVIII expression in canine livers and the long-term outcomes of non-myeloablative HLA-identical related hematopoietic cell transplantation.

Aliases

Rainer F. Storb is known by several aliases in the academic and scientific community. These include R Storb, R. Storb, Rainert Storb, Rainer Storb, R F Storb, R. F. Storb, and Rainer F. Storb.

Publication and Citation Metrics

Metric	Value
Citation Count	95,571
H-index	149
Paper Count	1,502

Publications:

Transcutaneous ultrasound mediated gene delivery into canine livers achieves therapeutic levels of FVIII expression.

DOI: 10.1182/bloodadvances.2021006016

Year: 2022

Conditioning Intensity and Peri-Transplant Flow Cytometric MRD Dynamics in Adult AML.

DOI: 10.1182/blood.2021014804

Year: 2022

Utility of the Treatment-Related Mortality (TRM) score to predict outcomes of adults with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation

DOI: 10.1038/s41375-022-01574-5

Year: 2022

Addition of Astatine-211-Labeled Anti-CD45 Antibody to TBI as Conditioning for DLA-Identical Marrow Transplantation: A Novel Strategy to Overcome Graft Rejection in a Canine Presensitization Model: "Radioimmunotherapy to Overcome Transfusion-Induced Sensitization".

DOI: 10.1016/j.jtct.2021.02.018

Year: 2021

Long-term Outcomes with Nonmyeloablative HLA-Identical Related Hematopoietic Cell Transplantation Using Tacrolimus and Mycophenolate Mofetil for Graft-versus-Host Disease Prophylaxis.

DOI: 10.1016/j.jtct.2020.10.016

Year: 2021

Commentary on the 1962 Transfusion paper by Don Thomas and Joe Ferrebee

DOI: 10.1111/trf.16684

Year: 2021

Cancers after HLA-matched related Bone Marrow Transplantation for Aplastic Anemia

DOI: 10.1038/s41409-021-01498-1

Year: 2021

Evolution of haematopoietic cell transplantation for canine blood disorders and a platform for solid organ transplantation

DOI: 10.1002/vms3.601

Year: 2021

A Phase I Trial of First-in-Human Alpha-Emitter Astatine-211-Labeled Anti-CD45 Antibody (211At-BC8-B10) in Combination with Fludarabine and TBI As Conditioning for Allogeneic Hematopoietic Cell Transplantation (HCT) for Patients with Refractory/Relapsed Leukemia or High-Risk Myelodysplastic Syndrome

DOI: 10.1016/S2666-6367(21)00083-X

Year: 2021

Allogeneic hematopoietic cell transplantation with non-myeloablative conditioning for patients with hematologic malignancies: improved outcomes over two decades

DOI: 10.3324/haematol.2020.248187

Year: 2020

What are the Psychological Impacts of Geographical Barriers?

How Does a Linac Work?

Why is Hysteroscopy Important in Cancer Diagnosis?

How can cancer patients manage stress and anxiety?

Is THC Approved for Cancer Treatment?

What is Laryngoscopy?

How Do Opioids Play a Role in Pain Management?

What Happens if There Is No Will?

What Are the Future Directions in Addressing Drug Target Alteration?

How is a Pap Smear Performed?

Partnered Content Networks

Relevant Topics